Manufacturers don’t use fast-track reimbursement in Europe. Although this seems like an oversight, there are six reasons explaining why it is not happening.
Using epidemiological data, a patient-based forecasting model projected the gene therapy market outlook until 2036, evaluating global developments and their impact. Despite uncertainties, it emphasized the importance of preparedness and sustainability for public health resource stakeholders.
France’s Health Innovation 2030 Plan Proposes to Adopt a Market Access Pathway Like the German System to Accelerate Patient Access to Innovative Medicines – What Changes Can Be Expected?
French lawmakers are setting the scene for a showdown with manufacturers defending their drug prices with R&D investment figures.
France’s healthcare industry strategic council CSIS met an agreement with the French Government to strengthen France’s appeal for HealthCare industries. Inbeeo dives in to investigate the impact on market access and pricing.
